|
|
Prepublished online as a Blood First Edition Paper on October 31, 2002; DOI 10.1182/blood-2002-05-1514.
 Previous Article | Table of Contents | Next Article 
Blood, 1 March 2003, Vol. 101, No. 5, pp. 1905-1912
IMMUNOBIOLOGY
Generating CTLs against the subdominant Epstein-Barr virus LMP1
antigen for the adoptive immunotherapy of EBV-associated
malignancies
Stephen Gottschalk,
Oliver L. Edwards,
Uluhan Sili,
M. Helen Huls,
Tatiana Goltsova,
Alan R. Davis,
Helen E. Heslop, and
Cliona M. Rooney
From the Center for Cell and Gene Therapy, Texas
Children's Cancer Center, Departments of Pediatrics, Medicine, and
Molecular Virology and Microbiology, Baylor College of Medicine,
Houston, TX.
The Epstein-Barr virus (EBV)-encoded LMP1 protein is expressed in
EBV-positive Hodgkin disease and is a potential target for cytotoxic
T-lymphocyte (CTL) therapy. However, the LMP1-specific CTL frequency is
low, and so far the generation of LMP1-specific CTLs has required
T-cell cloning. The toxicity of LMP1 has prevented the use of dendritic
cells (DCs) for CTL stimulation, and we reasoned that an inactive,
nontoxic LMP1 mutant ( LMP1) could be expressed in DCs and would
enable the activation and expansion of polyclonal LMP1-specific CTLs.
Recombinant adenoviral vectors expressing LMP1 or LMP1 were tested
for their ability to transduce DCs. LMP1 expression was toxic within 48 hours whereas high levels of LMP1 expression were achieved with
minimal toxicity. LMP1-expressing DCs were able to reactivate and
expand LMP1-specific CTLs from 3 healthy EBV-seropositive donors.
LMP1-specific T cells were detected by interferon- (IFN-)
enzyme-linked immunospot assay (ELISPOT) assays using the
HLA-A2-restricted LMP1 peptide, YLQQNWWTL (YLQ). YLQ-specific T cells
were undetectable (less than 0.001%) in donor peripheral blood
mononuclear cells (PBMCs); however, after stimulation the frequency
increased to 0.5% to 3.8%. Lysis of autologous target cells by CTLs
was dependent on the level of LMP1 expression. In contrast, the
frequency of YLQ-specific CTLs in EBV-specific CTLs reactivated
and expanded using lymphoblastoid cell lines was low and no
LMP1-specific cytotoxic activity was observed. Thus, LMP1 expression
in DCs is nontoxic and enables the generation of LMP1-specific CTLs for
future adoptive immunotherapy protocols for patients with LMP1-positive
malignancies such as EBV-positive Hodgkin disease. Targeting LMP1 in
these malignancies may improve the efficacy of current adoptive
immunotherapy approaches.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Smith, N. Wakisaka, T. Crough, J. Peet, T. Yoshizaki, L. Beagley, and R. Khanna
Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation
Blood,
June 11, 2009;
113(24):
6148 - 6152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Cohen, H. Kimura, S. Nakamura, Y.-H. Ko, and E. S. Jaffe
Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008
Ann. Onc.,
June 10, 2009;
(2009)
mdp064v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Bollard, S. Gottschalk, A. M. Leen, H. Weiss, K. C. Straathof, G. Carrum, M. Khalil, M.-f. Wu, M. H. Huls, C.-C. Chang, et al.
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
Blood,
October 15, 2007;
110(8):
2838 - 2845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ahmed, M. Ratnayake, B. Savoldo, L. Perlaky, G. Dotti, W. S. Wels, M. B. Bhattacharjee, R. J. Gilbertson, H. D. Shine, H. L. Weiss, et al.
Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells
Cancer Res.,
June 15, 2007;
67(12):
5957 - 5964.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Xu, T. Coleman, J. Zhang, A. Fagot, C. Kotalik, L. Zhao, P. Trivedi, C. Jones, and L. Zhang
Epstein-Barr Virus Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication in Primary Effusion Lymphomas
J. Virol.,
June 1, 2007;
81(11):
6068 - 6078.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al.
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study
Blood,
December 15, 2006;
108(13):
4163 - 4169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Smith, L. Cooper, M. Burgess, M. Rist, N. Webb, E. Lambley, J. Tellam, P. Marlton, J. F. Seymour, M. Gandhi, et al.
Functional Reversion of Antigen-Specific CD8+ T Cells from Patients with Hodgkin Lymphoma following In Vitro Stimulation with Recombinant Polyepitope
J. Immunol.,
October 1, 2006;
177(7):
4897 - 4906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ishida, T. Ishii, A. Inagaki, H. Yano, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda
Specific Recruitment of CC Chemokine Receptor 4-Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege
Cancer Res.,
June 1, 2006;
66(11):
5716 - 5722.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al.
Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes
J. Clin. Oncol.,
December 10, 2005;
23(35):
8942 - 8949.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Straathof, A. M. Leen, E. L. Buza, G. Taylor, M. H. Huls, H. E. Heslop, C. M. Rooney, and C. M. Bollard
Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma
J. Immunol.,
September 15, 2005;
175(6):
4137 - 4147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Flynn, M. Pistello, P. Isola, L. Zaccaro, B. Del Santo, E. Ricci, D. Matteucci, and M. Bendinelli
Adoptive Immunotherapy of Feline Immunodeficiency Virus with Autologous Ex Vivo-Stimulated Lymphoid Cells Modulates Virus and T-Cell Subsets in Blood
Clin. Vaccine Immunol.,
June 1, 2005;
12(6):
736 - 745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. M. Straathof, C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, et al.
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes
Blood,
March 1, 2005;
105(5):
1898 - 1904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Bartlett
Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy
Hematology,
January 1, 2005;
2005(1):
245 - 251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Bollard, L. Aguilar, K. C. Straathof, B. Gahn, M. H. Huls, A. Rousseau, J. Sixbey, M. V. Gresik, G. Carrum, M. Hudson, et al.
Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease
J. Exp. Med.,
December 20, 2004;
200(12):
1623 - 1633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Marshall, L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Blood,
March 1, 2004;
103(5):
1755 - 1762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Comoli, R. De Palma, S. Siena, A. Nocera, S. Basso, F. Del Galdo, R. Schiavo, O. Carminati, A. Tagliamacco, G. F. Abbate, et al.
Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma
Ann. Onc.,
January 1, 2004;
15(1):
113 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tellam, G. Connolly, N. Webb, J. Duraiswamy, and R. Khanna
Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity
Blood,
December 15, 2003;
102(13):
4535 - 4540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Heslop, F. K. Stevenson, and J. J. Molldrem
Immunotherapy of Hematologic Malignancy
Hematology,
January 1, 2003;
2003(1):
331 - 349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
